BiotechTube
Home/Pipeline/GAIA-102 (fulamleucel) (iv + pretreatment)

GAIA-102 (fulamleucel) (iv + pretreatment)

Neuroblastoma

Early clinical trialActive

Key Facts

Indication
Neuroblastoma
Phase
Early clinical trial
Status
Active
Company
GAIA BioMedicine

About GAIA BioMedicine

A biotech company developing off-the-shelf, non-genetically modified NK-like cell therapies to eliminate solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Neuroblastoma Drugs

DrugCompanyPhase
Neuroblastoma Risk StratificationQuibimResearch
VNX-201Vironexis BiotherapeuticsPreclinical
GD2-GD3 Bispecific VaccineY-mAbs TherapeuticsEarly Clinical
DANYELZA® (naxitamab)SERB PharmaceuticalsApproved
Dinutuximab (OP-08/Unituxin®)Ohara PharmaceuticalApproved